A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

ClinicalTrials.gov ID: NCT07491172

Public ClinicalTrials.gov record NCT07491172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 28, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

Study identification

NCT ID: NCT07491172
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: CRISPR Therapeutics AG; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

CTX310 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 20, 2024
Primary completion: May 31, 2027
Completion: May 31, 2028
Last update posted: Mar 23, 2026

2024 – 2028

United States locations

U.S. sites: 7
U.S. states: 4
U.S. cities: 7

Facility	City	State	ZIP	Site status
Research Site 10	Jacksonville	Florida	32216	Not yet recruiting
Research Site 17	Orlando	Florida	32789	Not yet recruiting
Research Site 11	Port Orange	Florida	32127	Not yet recruiting
Research Site 14	Durham	North Carolina	27710	Not yet recruiting
Research Site 13	High Point	North Carolina	27260	Not yet recruiting
Research Site 9	Cleveland	Ohio	44195	Not yet recruiting
Research Site 12	Portland	Oregon	97239	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07491172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 23, 2026 · Synced Apr 28, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07491172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →